On September 26, 2017, the Centers for Disease Control and Prevention (CDC) issued a press release titled, “STDs (sexually transmitted diseases) at record high, indicating urgent need for prevention.” Unfortunately, but not surprisingly, marked increases in sexually transmitted infections (STIs) are occurring here in Oregon as well. This CD Summary presents the data from Oregon and provides recommendations for providers for screening, diagnosing, treating, and preventing these infections.

OREGON DATA

Chlamydia, gonorrhea and syphilis are the most common bacterial STIs in Oregon.† During 2017, these three infections continued to increase alarmingly (Figures 1–3), representing indisputable statewide epidemics with little evidence of abating.

Although these diseases have several aspects in common (e.g., age, sex, and race distributions), and each presents unique challenges (Figures 4–6).

Dwindling antibiotic choices confound health professionals who treat people with gonorrhea.‡ Ophthalmic morbidity, including blindness, and other seldom-seen manifestations of syphilis are teaching a whole new generation of clinicians and public health professionals about “the great imitator.” And tragically, 20 babies were born with congenital syphilis in Oregon during 2015–2017.

WHY IS THIS HAPPENING?

Although some of the increases in reported cases (Figures 7–8, verso) can be attributed to increased sensitivity of convenient screening tests (i.e., for chlamydia and gonorrhea), we believe that most of the observed increase represents a true increase in incidence; and after much study far too complex to be understood by nonepidemiologists have concluded that it might have a lot to do with sex.‡ Breaking it down still further, here are some of the specific drivers of the epidemic:

1. increases in intercourse without condoms due to reduced risk of human immunodeficiency virus (HIV) transmission from people with HIV who take anti-retroviral medicines;
2. reduced local public health infrastructure and capacity to investigate cases, notify partners and bring them in for screening and treatment;

‡ the act, that is, not the gender
3. abundance of mobile apps facilitating “hook-ups” with anonymous sexual partners; and
4. use of methamphetamine and other stimulants, increasing sexual drive while decreasing inhibition.6

SCREENING AND TREATMENT: EASIER SAID THAN DONE

An asymptomatic infectious period is common to all three bacterial STIs. This means that transmission can be prevented by frequent screening and treatment of at-risk groups to shorten the infectious period. This is the rationale behind measures to test and treat partners. Some evidence suggests that screening of people at highest risk as frequently as every three months is an efficient way to prevent additional infections. In Oregon those at highest risk include:

- men who have sex with men (MSM),
- methamphetamine users,
- people with HIV, and
- people who have previously had the same or another bacterial STI.

Frequent screening requires systematic processes for identifying people who should be screened and ensuring that the screening is done. Currently, most screening tests for STIs take place within healthcare settings. Yet, little evidence is available to suggest that health care providers consistently collect and record sexual orientation or establish systems to implement regular screening for those who need it that don’t overly depend on busy clinicians who are understandably focused on the presenting complaint.

Cost-effectiveness literature provides some support for expanded screening, especially among men who have sex with men, and in corrections and drug-treatment settings. The benefits of screening however, typically accrue to society at large, and not to the financial “bottom line” of the jail, drug-treatment center, or health insurer who incurs the initial cost.7

Moreover, for all three STIs, individual short-term morbidity and acuity are low: most people never know they have (or had) syphilis, gonorrhea or chlamydia unless they get tested. Nevertheless, high lifetime incidences of tubal infertility, ectopic pregnancy and chronic pelvic pain are the legacy of unchecked chlamydia and gonorrhea. And even one case of congenital syphilis can cost a young life or result in lifelong disability.

WHAT IS TO BE DONE?

Sexual history. Physicians and other healthcare providers should make a habit of taking a sexual history from everyone aged ≥13 years, including whether they are sexually active, frequency of sex, number of partners, and gender of sex partners.

Screen and treat. Screening recommendations, based on sexual history for chlamydia, gonorrhea and syphilis are in the Table. In addition, every adult should be screened for HIV at least once — and more frequently for persons in higher-risk groups (e.g., MSM, injection drug users).

Expedit ed partner therapy (EPT). Health care providers should offer and prescribe treatment for partners of patients diagnosed with gonorrhea or chlamydia, a practice known as “expedited partner therapy,” which is not only legal in Oregon, but encouraged by the Oregon Public Health Division and by CDC when partners are unlikely to seek evaluation, testing and treatment. Randomized trials have demonstrated that EPT prevents recurrent infections. Logically, EPT leads to reduced transmission of STIs within a social network.

IT TAKES A VILLAGE

Public health agencies have been making similar recommendations for years with questionable impact. In the absence of game-changing treatment discoveries or immunizations, substantial reductions in STI morbidity will likely require systematic changes that drive comprehensive screening and facilitate treatment.

1. Collecting and recording sexual histories and reflexive screening can be done routinely by someone other than the physician or other licensed health care provider.
2. Offices, clinics, hospitals, and integrated health care systems will need to modify intake procedures to include routine sexual histories, reflexive testing and treatment; create standing orders for screening; and modify the electronic medical record to promote or emphasize sexual history and appropriate screening.
3. Insurers and others could encourage collection of sexual histories and STI screening by reviewing reimbursement practices to ensure that patients don’t incur unexpected charges for appropriate STI screening; by creating explicit quality metrics related to sexual history collection and STI screening; and by creating meaningful incentives for these practices.

We need your help! Health care professionals, governmental public health agencies, insurance executives, community organizations, patient advocacy groups, businesses, public policy professionals, economists and academic partners all have a role to play if we are to turn the tide.

FOR MORE INFORMATION
- OHA STD/HIV web page
- Oregon STD Data

REFERENCES
## Table. Screening recommendations for bacterial sexually transmitted infections in Oregon

<table>
<thead>
<tr>
<th>Disease</th>
<th>Who should be screened</th>
<th>Frequency</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Chlamydia and Gonorrhea          |                                                             |                                  | * Everyone with a positive test should be retested 3 months after treatment to screen for reinfection, since reinfection after treatment is very common.  
  • Oropharynx should be screened for gonorrhea if history of oral contact, while screening oropharynx is not recommended for chlamydia. |
| Women <25 years of age           | At least annually if sexually active                        |                                  |                                                                                                                                         |
| Women ≥25 years of age if increased individual risk or high prevalence setting | At least annually if sexually active                        |                                  | • Individual risk factors include: previous STI, recreational drug use (particularly methamphetamine and other stimulants), multiple sex partners, condomless intercourse.  
  • High-prevalence settings include, but are not limited to: correctional facilities, adolescent clinics, and sexually transmitted disease clinics. |
| Young men if increased individual risk or high prevalence setting | At least annually if sexually active                        |                                  | • Individual risk factors include: previous STI, men who have sex with men, recreational drug use (particularly methamphetamine and other stimulants), multiple sex partners, condomless intercourse.  
  • High-prevalence settings include, but are not limited to: correctional facilities, adolescent clinics, and sexually transmitted disease clinics. |
| Men who have sex with men         | At least annually if sexually active                        | Test at sites of contact:        | • urethra and rectum for chlamydia;  
  • urethra, rectum, and oropharynx for gonorrhea  
  • screen as often as every three months if at increased risk. |
| People with HIV infection         | At least annually if sexually active                        |                                  |                                                                                                                                         |
| Pregnant women <25 years of age  | At prenatal visit                                           |                                  | • Individual risk factors include: previous STI, recreational drug use (particularly methamphetamine and other stimulants), multiple sex partners, condomless intercourse.  
  • High-prevalence settings include, but are not limited to: correctional facilities, adolescent clinics and sexually transmitted disease clinics.  
  • Pregnant women should undergo test for cure 3–4 weeks after treatment. |
| Pregnant women ≥25 years of age if increased individual risk or high prevalence setting | At prenatal visit                                           | Pregnant women should undergo test for cure 3–4 weeks after treatment. |                                                                                                                                                                                                 |
| Syphilis                          |                                                             |                                  | Screen for syphilis by collecting serum for Rapid Plasma Reagin (RPR) test initially followed by a treponeme-specific antibody test such as *Treponema pallidum* Partical Agglutination test (TPPA) if feasible. Alternatively, use a so-called “reverse algorithm” that tests serum initially for treponemal antibodies, usually via an automated immunoassay, followed by RPR if initial antibody test is positive. Reverse-algorithm testing has become common among commercial laboratories in Oregon. |
| Sexually active people with HIV   | At least annually                                           |                                  |                                                                                                                                                                                                 |
| Sexually active men who have sex with men | At least annually                                           | Screen as often as every three months if at increased risk. |                                                                                                                                                                                                 |
| Sexually active people who use recreational drugs, particularly methamphetamine and other stimulants | At least annually                                           |                                  |                                                                                                                                                                                                 |
| All pregnant women                | • First prenatal visit  
  • 28 weeks’ gestation  
  • At delivery | Increased screening is recommended due to ongoing syphilis epidemic and increases in congenital syphilis in Oregon. |                                                                                                                                                                                                 |

*The careful reader will note that these recommendations differ slightly from CDC’s ([www.cdc.gov/std/tg2015/screening-recommendations.htm](http://www.cdc.gov/std/tg2015/screening-recommendations.htm)) for sexually transmitted disease screening either to simplify or consolidate (chlamydia and gonorrhea) or to include additional recommendations as a consequence of ongoing epidemics (syphilis and gonorrhea) in Oregon.*
Providence Portland Medical Center designates this enduring material for a maximum of .5 AMA PRA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Portland Providence Medical Center is accredited by the Oregon Medical Association to sponsor continuing medical education of physicians.

You can get this document in other languages, large print, braille or a format you prefer. Contact the Public Health Division at 971-673-1222. We accept all relay calls or you can dial 711 for TTY.